Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Operating Expenses (2023 - 2025)

Spyre Therapeutics' Other Operating Expenses history spans 2 years, with the latest figure at $10.0 million for Q2 2025.

  • For Q2 2025, Other Operating Expenses changed N/A year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, changed N/A, while the annual FY2025 figure was $10.0 million, N/A changed from the prior year.
  • Other Operating Expenses reached $10.0 million in Q2 2025 per SYRE's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $130.5 million in Q2 2023 to a low of $1.8 million in Q4 2023.